Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025

Core Insights - Pulmonx Corporation will release its financial results for Q3 2025 on October 29, 2025, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, aimed at treating patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized in global treatment guidelines as a standard care option for improving patient outcomes [3]